Immuron Ltd (IMC)
Australian Securities Exchange · Australia · prices in AUD · close of 22 Oct 2026
Key indicators
| Last close | AUD 0.040 |
|---|---|
| 52-week range | 0.026 – 0.098 |
| Return, 1 month / 3 months | −13.0% / +14.3% |
| Return, 1 year / 3 years | −52.4% / −46.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 48 |
| Volatility (1 year) | 112.3% |
| Worst drawdown (1 year) | -72.3% |
| Average daily value traded | 0.02M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Immuron Ltd is an Australian biopharmaceutical company that develops oral immunotherapy products derived from hyperimmune bovine colostrum. Its main commercial product, Travelan, is a dietary supplement taken by travellers to help reduce the risk of travellers' diarrhoea. The company also develops prescription products for infectious diseases of the gut, including a candidate for Clostridioides difficile infection, and works with research and medical partners. Immuron is based in Melbourne, Australia, and its products are sold in several overseas markets.
Immuron Ltd trades under the code IMC on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Immuron Ltd (IMC) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.040 on 22 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 934 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 52.4% and over the last three months it rose 14.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.4% | ||
| From 52-week high | -57.4% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 14.3% | ||
| 6-month return | 25.0% | ||
| 12-month return, skipping the last month | -45.2% | ||
| Stability (higher is calmer) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 112.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -72.3% | ||
| Liquidity | 41 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M AUD | ||
| Zero-volume days | 25.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +11.1% |
|---|---|
| 1 month | −13.0% |
| 3 months | +14.3% |
| 6 months | +25.0% |
| 1 year | −52.4% |
| 3 years | −46.7% |
| 5 years | −68.0% |
Signals
| 50-day / 200-day average | 0.042 / 0.036 |
|---|---|
| Golden / death cross (60 days) | Golden, 39 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.002 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.